News Conference News ACC 2023 RAPID-HF: Rate-Adaptive Pacing Doesn’t Help in HFpEF Todd Neale March 05, 2023
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2020 Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS Todd Neale April 03, 2020
News Conference News ACC 2019 AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI Caitlin E. Cox March 17, 2019
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ACC 2018 Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis Todd Neale March 12, 2018
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017